Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
IrAEs, especially thyroid irAEs, as well as mild or single-system irAEs, may serve as predictors of improved efficacy in advanced NSCLC patients receiving PD-1 inhibitors combination therapy.
Authors
- Yuanyuan Li (ORCID: https://orcid.org/0000-0003-2981-8976)
- Wenbo Ding (ORCID: https://orcid.org/0000-0003-1360-4922)
- Qiaomei Lv
- Yuhao Li
- Wei Wang (ORCID: https://orcid.org/0009-0003-7539-9394)
- Xiaohong Xie (ORCID: https://orcid.org/0000-0002-3426-4253)
Institutions
- China Medical University (CN)
- Eastern Liaoning University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12885-024-13220-7
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57